Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.1.47 - 1-alkyl-2-acetylglycerophosphocholine esterase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.
Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells.
Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.
Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma.
Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
Lack of evidence for associations between plasma platelet-activating factor acetylhydrolase deficiency and schizophrenia.
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency.
Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma.
Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan.
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
Study of platelet-activating factor acetylhydrolase in the perioperative period of patients undergoing cardiac surgery.
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice.
[Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke]
Abetalipoproteinemia
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
Acquired Immunodeficiency Syndrome
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome.
Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.
Lp-PLA2: a new kid on the block.
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
Acute Kidney Injury
The role of lipoprotein-associated phospholipase A2 in acute kidney injury of septic mice.
Acute Lung Injury
DIFFERENTIAL EXPRESSION OF PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE IN LUNG MACROPHAGES.
Lung production of platelet-activating factor acetylhydrolase in oleic acid-induced acute lung injury.
Adenocarcinoma
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Adenomatous Polyposis Coli
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Aggressive Periodontitis
Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis.
Differential platelet-activating factor synthesis by monocytes and polymorphonuclear leukocytes from subjects with localized aggressive periodontitis.
Albuminuria
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.
[Informatori biologici per ischemia miocardica silente: approccio diagnostico e prognostico.]
Alopecia
ROBO4 deletion ameliorates PAF-mediated skin inflammation via regulating the mRNA translation efficiency of LPCAT1/LPCAT2 and the expression of PAF receptor.
Alzheimer Disease
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan.
Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [(18)F]GSK2647544 in Healthy Male Subjects.
Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease.
Lipoprotein-associated phospholipase A2: The story continues.
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Anaphylaxis
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014.
Anaphylactic reaction induced by Toxoplasma gondii-derived heat shock protein 70.
Basal platelet-activating factor acetylhydrolase: Prognostic marker of severe Hymenoptera venom anaphylaxis.
Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study.
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models.
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Pathophysiology of food-induced anaphylaxis.
Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Angina Pectoris
Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease.
Angina, Stable
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Platelet-activating factor acetylhydrolase activity in patients with chronic stable angina (preliminary results).
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty.
Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina.
Angina, Unstable
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Angioedema
Hereditary angioedema attack: what happens to vasoactive mediators?
Antiphospholipid Syndrome
Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome.
Aortic Aneurysm
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Aortic Aneurysm, Abdominal
Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese.
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Aortic Valve Disease
Circulating Lp-PLA2 is associated with high valvuloarterial impedance and low arterial compliance in patients with aortic valve bioprostheses.
Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.
Aortic Valve Stenosis
Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study.
Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.
Lipoprotein-associated phospholipase A2 and aortic stenosis: biomarker or new target for an old foe?
Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Arteritis
Effect of Treatment for 12 weeks with Rilapladib, a Lipoprotein-associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed with 18F-Fluorodeoxyglucose-PET Imaging.
Arthritis
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Arthritis, Juvenile
Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity.
Arthritis, Rheumatoid
Atherosclerosis assessment and rheumatoid arthritis.
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Release of platelet-activating factor in systemic lupus erythematosus.
Asthma
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.
Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma.
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma.
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population.
PAF acetylhydrolase gene polymorphisms and asthma severity.
PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency.
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma.
Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy.
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.
[Analysis of platelet-activating factor and its effect on the lung]
[Increased plasma levels of platelet-activating factor (PAF) and low serum PAF acetylhydrolase (PAFAH) activity in adult patients with bronchial asthma]
Atherosclerosis
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.
A pleiotropic QTL on 2p influences serum Lp-PLA2 activity and LDL cholesterol concentration in a baboon model for the genetics of atherosclerosis risk factors.
A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice.
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome.
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction.
ANNALS EXPRESS: Lipoprotein-Associated Phospholipase A2: a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidemic children.
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A? (Lp-PLA?): a review.
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.
Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS.
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis.
Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.
Association of lipoprotein-associated phospholipase A2 and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA).
Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study.
Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Association of PAF and its metabolic enzymes with GGT and the Fatty Liver Index in healthy volunteers.
Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients.
Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques.
Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Atherosclerosis assessment and rheumatoid arthritis.
Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Clinical aspects of plasma platelet-activating factor-acetylhydrolase.
Clinical Evaluation and Test of a Modified Lp-PLA2 Kit in Diagnosing Atherosclerosis.
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?
Darapladib for the treatment of cardiovascular disease.
Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2.
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis.
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.
Expression of Hypoxia-Inducible Factor-1? (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population.
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Free fatty acids to predict recurrent ischemic stroke.
HDL capacity to inhibit LDL oxidation in well-trained triathletes.
High density lipoprotein suppresses lipoprotein associated phospholipase A2 in human monocytes-derived macrophages through peroxisome proliferator-activated receptor-? pathway.
Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome.
Impact of a non-synonymous Q281R polymorphism on structure of human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2 ).
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs.
Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X.
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Juvenile rheumatoid arthritis.
Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice.
Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children.
Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.
Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.
Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study).
Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Lipoprotein-associated phospholipase A2 (Lp-PLA_2): A novel and promising biomarker for cardiovascular risks assessment.
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
Lipoprotein-associated phospholipase A2 and coronary heart disease.
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Lipoprotein-associated phospholipase A2 as a target of therapy.
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.
Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).
Lipoprotein-Associated Phospholipase A2 Regulates Macrophage Apoptosis via the Akt and Caspase-7 Pathways.
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Lipoprotein-associated phospholipase A2: The story continues.
Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Lp-PLA2 Inhibition-The Atherosclerosis Panacea?
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events.
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Lp-PLA2: an emerging biomarker of coronary heart disease.
Maternal and fetal plasma platelet-activating factor-acetylhydrolase activity and distribution in pre-eclampsia.
Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.
Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population.
New advances in drug discovery.
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways.
Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL.
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Periodontal microbiota and phospholipases: The Oral Infections and Vascular Disease Epidemiology Study (INVEST).
Phospholipase A2 inhibitors.
Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage.
Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Platelets inhibit the activity of platelet-activating factor acetylhydrolase in monocyte-derived macrophages.
Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease.
Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle.
Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1? and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Regression of atherosclerosis in apolipoprotein E-deficient mice by lentivirus-mediated gene silencing of lipoprotein-associated phospholipase A2.
Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis.
Relative sensitivities of plasma lecithin:cholesterol acyltransferase, platelet-activating factor acetylhydrolase, and paraoxonase to in vitro gas-phase cigarette smoke exposure.
Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
Role of lipoprotein-associated phospholipase A2 in atherosclerosis.
Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
SB-480848. GlaxoSmithKline.
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate- RhoA-p38 mitogen-activated protein kinase pathway.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Synthesis and Automated Labeling of [18F]Darapladib, a Lp-PLA2 Ligand, as Potential PET Imaging Tool of Atherosclerosis.
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
The diagnostic efficacy and predictive value of combined lipoprotein laboratory indexes for atherosclerosis.
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
The Relationship Between Lipoprotein-Associated Phospholipase A(2), Cholesteryl Ester Transfer Protein and Lipid Profile and Risk of Atherosclerosis in Women with Iron Deficiency Anaemia.
The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency.
The Role of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease.
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
The role of phospholipases in lipid modification and atherosclerosis.
Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine.
[Association of lipoprotein-associated phospholipase activity A2 with cardiovascular risk factors].
[Cerebral atherosclerosis: a biomarker profile].
[Changes of serum lipoprotein-related phospholipase A2 in patients with white matter lesion based on KIM classification and its correlation with carotid atherosclerotic plaque].
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
[Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Atrial Fibrillation
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation.
Bacterial Infections
Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections.
Basal Ganglia Hemorrhage
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
beta-Thalassemia
Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients.
Brain Diseases
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality.
Brain Infarction
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Brain Ischemia
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia.
Breast Neoplasms
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers.
Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity.
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Bronchopulmonary Dysplasia
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia.
Calcinosis
A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction.
Carcinogenesis
Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma.
Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Carcinoma
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.
Carcinoma, Hepatocellular
Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.
Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.
Carcinoma, Squamous Cell
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Cardiac Complexes, Premature
Phospholipase A2 and Ischemic Stroke Etiology.
Cardiomyopathy, Dilated
Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese.
[Correlation between desmin gene, platelet-activating factor acetylhydrolase gene and dilated cardiomyopathy]
Cardiomyopathy, Hypertrophic
Association of a G994 --> T (Val279 --> Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy.
Cardiotoxicity
Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.
Cardiovascular Diseases
?3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models.
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.
A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT).
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A? (Lp-PLA?): a review.
Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NF?B pathways.
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis.
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Biomarkers for Prediction of Cardiovascular Events in Community-Dwelling Adults Aged 40 or Older.
Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?
Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A2 for assessment of cardiovascular diseases.
Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation.
Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women.
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.
Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population.
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Developing and assessing cardiovascular biomarkers.
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Effects of A379V variant of the Lp-PLA 2 gene on Lp-PLA 2 activity and markers of oxidative stress and endothelial function in Koreans.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.
Effects of lipoprotein-associated phospholipase A2 on arginase/nitric oxide pathway in hemodialysis patients.
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Expression of Hypoxia-Inducible Factor-1? (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population.
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study).
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Impact of 8-week linoleic acid intake in soy oil on Lp-PLA2 activity in healthy adults.
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.
Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.
Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.
Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review.
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for "prime time".
Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study.
Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome.
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?
Lipoprotein-associated phospholipase A2: Review and recommendation of a clinical cut point for adults.
Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes.
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations.
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Measuring lipoprotein-associated phospholipase A2 activity in China: Protocol comparison and recalibration.
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management.
Overexpression of porcine lipoprotein-associated phospholipase A2 in swine.
Oxidized LDL induces procoagulant profiles by increasing lysophosphatidylcholine levels, lysophosphatidylethanolamine levels, and Lp-PLA2 activity in borderline hypercholesterolemia.
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Phospholipid mediators in the vessel wall: involvement in atherosclerosis.
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials.
Platelet-activating factor acetylhydrolases: An overview and update.
Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis.
Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models.
Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease.
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Switching the substrate specificity of lysoplasmalogen-specific phospholipase D.
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice.
The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of the lipoprotein-associated phospholipase A2-bound apoB.
The relation between Lp-PLA2 levels with periodic limb movements.
The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors: Tehran Lipid and Glucose Study.
The Role of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease.
The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review.
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men.
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
[Development and application of monoclonal antibodies anti-human lipoprotein-associated phospholipase A2].
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
[Lp-PLA2 and sPLA2: cardiovascular biomarkers].
Carotid Artery Diseases
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Association of PLA2G7 polymorphisms with carotid atherosclerosis in hypertensive Japanese.
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.
Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis.
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Carotid Stenosis
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Carotid Plaque Inflammation Assessed by 18F-FDG PET/CT and Lp-PLA2 Is Higher in Symptomatic Patients.
Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque.
Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome.
LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 AS A MARKER OF VULNERABLE ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH INTERNAL CAROTID ARTERY STENOSIS.
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations.
Pro B-type Natriuretic Peptide and Midregional Proadrenomedullin are Associated with Incident Carotid Stenosis During Long Term Follow-up.
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
Central Nervous System Infections
Platelet-activating factor acetylhydrolase activity in cerebrospinal fluid of children with acute systemic or neurological illness.
Cerebral Hemorrhage
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
Cerebral Infarction
Carotid artery color Doppler ultrasonography and plasma levels of lipoprotein-associated phospholipase A2 and cystatin C in arteriosclerotic cerebral infarction.
Effects of dl-3-n-butylphthalide on serum lipoprotein-associated phospholipase A2 and hypersensitive C-reactive protein levels in acute cerebral infarction.
Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction.
Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage.
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
[Analysis of 994(G--> T) mutation in the plasma platelet-activating factor acetylhydrolase gene in the patients with cerebral infarction]
Cerebral Small Vessel Diseases
Association of neuroimaging markers of cerebral small vessel disease with short-term outcomes in patients with minor cerebrovascular events.
Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment.
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Cerebrovascular Disorders
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.
Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
The emerging role of lipoprotein-associated phospholipase A2 in cerebrovascular disease.
Cholangiocarcinoma
MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Cholestasis
Serum PAF acetylhydrolase and chronic cholestasis.
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Chondrocalcinosis
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Chronic Limb-Threatening Ischemia
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
Chronic Periodontitis
Activity of platelet activating factor acetylhydrolase following phase I periodontal therapy.
Lipoprotein-associated phospholipase A2 and serum lipid levels in subjects with chronic periodontitis and hyperlipidemia.
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
Classical Lissencephalies and Subcortical Band Heterotopias
A novel neurological mutant mouse, yotari, which exhibits reeler-like phenotype but expresses CR-50 antigen/reelin.
Characterization and chromosomal mapping of two pseudogenes of the mouse Pafaha/Lis1 gene: retrointegration hotspots in the mouse genome.
Cloning and expression of a cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase.
Expression of a 45K subunit of platelet-activating factor acetylhydrolase in the developing mouse cerebellum.
Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.
Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]
PAFAH1B1 haploinsufficiency disrupts GABA neurons and synaptic E/I balance in the dentate gyrus.
Predominant localization of the LIS family of gene products to Cajal-Retzius cells and ventricular neuroepithelium in the developing human cortex.
The phospholipase complex PAFAH Ib regulates the functional organization of the Golgi complex.
[Molecular mechanism of lissencephaly--how LIS1 and NDEL1 regulate cytoplasmic dynein?]
Coinfection
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Colitis, Ulcerative
Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis.
Relationship between the platelet activating factor acetylhydrolase gene and intractability of ulcerative colitis.
Colorectal Neoplasms
Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.
Coma
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Corneal Edema
Corneal PAF acetylhydrolase increases in anterior segment ischemia in rabbits.
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Association between Lipoprotein-Associated Phospholipase A(2) Gene Polymorphism and Coronary Artery Disease in the Chinese Han Population.
Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients.
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Comparison of Change in Coronary Atherosclerosis in Patients With Stable Versus Unstable Angina Pectoris Receiving Statin Therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] Study).
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease.
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease.
Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study).
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Letter regarding article by Winkler et al, "Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study".
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.
Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids.
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients.
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease.
Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.
Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis.
Plasma platelet-activating factor degradation in patients with severe coronary artery disease.
Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
Polyunsaturated Fatty Acids and Their Correlations with Parameters of Oxidative/Antioxidant Potential of the Blood and Lipoprotein-Associated Phospholipase A2 in Coronary Atherosclerosis.
Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina.
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease.
Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis.
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme.
The diagnostic efficacy and predictive value of combined lipoprotein laboratory indexes for atherosclerosis.
The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease.
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
[Red blood cell distribution width combined with lipoprotein-associated phospholipase A2 detection for improving diagnostic accuracy of coronary artery stenosis in patients with coronary artery disease].
Coronary Disease
Advantages of the lipoprotein-associated phospholipase A2 activity assay.
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.
Biological variability of lipoprotein-associated phospholipase A2 activity in healthy individuals.
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females.
Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study.
Estrogen and promoter methylation in the regulation of PLA2G7 transcription.
Evaluation of recombinant enzyme calibration to harmonize lipoprotein-associated phospholipase A2 activity results between instruments.
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Lipoprotein-associated phospholipase A2 and coronary heart disease.
Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Lipoprotein-associated phospholipase A2 as a target of therapy.
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis.
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Lipoprotein-associated phospholipase A2: Review and recommendation of a clinical cut point for adults.
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Lp-PLA2: an emerging biomarker of coronary heart disease.
Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population.
Performance Characteristics and Clinical Value of the Lipoprotein-Associated Phospholipase A2 by an Enzymatic Kinetic Method.
Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
PLA2G7 gene polymorphisms and coronary heart disease risk: A meta-analysis.
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
PLAC Test for Lp-PLA2 Activity to Predict Coronary Heart Disease.
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease.
Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China.
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction.
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
[Challenges in liver diseases and transplantation].
[Lipoprotein-associated phospholipase A2: importance and perspectives]
Coronary Stenosis
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
[Red blood cell distribution width combined with lipoprotein-associated phospholipase A2 detection for improving diagnostic accuracy of coronary artery stenosis in patients with coronary artery disease].
COVID-19
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Crohn Disease
PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.
Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease.
Cushing Syndrome
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
CONDITIONING FACTORS FOR HIGH CARDIOVASCULAR RISK IN PATIENTS WITH CUSHING SYNDROME.
Cysts
No relation between biomarkers at age 47-49 and aortic diameter after 14-19 years of follow-up - a population-based study.
Delirium
Association of Carotid Plaque and Serum Lipoprotein-Associated Phospholipase A2 (LP-PLA2) with Postoperative Delirium in Geriatric Patients Undergoing Hip Replacement: A Prospective Cohort Study.
Dementia
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Inflammatory markers and the risk of dementia and Alzheimer's disease: A meta-analysis.
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Dementia, Vascular
[Association of serum lipoprotein-associated phospholipase A2 with vascular dementia after ischemic stroke].
Dengue
Serum platelet-activating factor acetylhydrolase activity in dengue.
[Serum platelet-activating factor acetylhydrolase activity in dengue patients of African or mestizo descendency].
Dermatitis, Atopic
Serum platelet-activating factor acetylhydrolase activity in patients with atopic dermatitis.
Diabetes Complications
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Diabetes Mellitus
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2.
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus.
Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus.
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus.
Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.
Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus.
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Role of vitamin D in risk factors of patients with type 2 diabetes mellitus.
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
[Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk].
Diabetes Mellitus, Type 1
Altered platelet activating factor metabolism in insulin dependent diabetes mellitus.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.
Characterization of PAF-AH Ib1 in NOD mice: PAF-AH may not be a candidate gene of the diabetes susceptibility Idd4.1 locus.
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.
Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes.
Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.
Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes.
Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus.
Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.
Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy.
The relationship between concentrations of magnesium and oxidized low density lipoprotein and the activity of platelet activating factor acetylhydrolase in the serum of patients with type 1 diabetes.
Diabetes Mellitus, Type 2
Altered platelet activating factor metabolism in insulin dependent diabetes mellitus.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes.
Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Future Risk of Type 2 Diabetes: Results from the Cardiovascular Health Study.
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.
Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus.
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT).
Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus.
Role of vitamin D in risk factors of patients with type 2 diabetes mellitus.
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
[Diagnostic value of combined detection of different indicators for type 2 diabetes mellitus combined with atherosclerotic disease].
Diabetes, Gestational
Activity and distribution of plasma platelet-activating factor acetylhydrolase in women with gestational diabetes mellitus and their neonates.
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.
Maternal Gestational Diabetes Mellitus increases placental and foetal lipoprotein-associated Phospholipase A2 which might exert protective functions against oxidative stress.
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance.
Diabetic Foot
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Diabetic Nephropathies
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Diabetic Retinopathy
"Association between platelet activating factor acetylhydrolase and diabetic retinopathy: Does inflammation affect the retinal status?".
Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study.
Digestive System Diseases
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Dyslipidemias
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia.
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia.
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1? and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Encephalomyelitis
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Encephalomyelitis, Autoimmune, Experimental
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Endometriosis
Platelet-activating factor acetylhydrolase activity in peritoneal fluids of women with endometriosis.
Endotoxemia
Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver.
Enterocolitis, Necrotizing
Absorption of platelet-activating factor acetylhydrolase by rat intestine.
Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis.
Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis.
Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis.
Serum PAF acetylhydrolase increases during neonatal maturation.
The prevalence of platelet activating factor acetylhydrolase single nucleotide polymorphisms in relationship to necrotizing enterocolitis in Northwest Louisiana infants.
The prevention of necrotizing enterocolitis. The role of platelet-activating factor acetylhydrolase.
The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis.
Epilepsy
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Erectile Dysfunction
Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
Essential Hypertension
Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Fasciculation
Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.
Fatty Liver
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Exploration of serum sensitive biomarkers of fatty liver in dairy cows.
Fetal Death
Effect of dexamethasone on rat plasma platelet activating factor acetylhydrolase during the perinatal period.
Foot Ulcer
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Glioma
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
Glomerulonephritis
Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis.
Glomerulonephritis, IGA
Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy.
Genetics of immunoglobulin A nephropathy.
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy.
Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy.
Glucose Intolerance
Inhibition of Ca2+-independent phospholipase A2 results in insufficient insulin secretion and impaired glucose tolerance.
Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.
Heart Diseases
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Is there a relationship between small, dense LDL and lipoprotein--associated phospholipase A2 mass in dialysis patients?
Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease.
Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
[Lipoprotein-associated phospholipase A(2) and stroke]
Heart Failure
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam Study.
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community.
Hematologic Neoplasms
Fighting Cancer Stem Cell Fate by Targeting LIS1 a WD40 Repeat Protein.
Hemolytic-Uremic Syndrome
Platelet-activating factor acetylhydrolase gene mutation in Japanese children with Escherichia coli O157-associated hemolytic uremic syndrome.
Hemorrhagic Stroke
Lipoprotein-associated Phospholipase A2 during the Hyperacute Stage of Ischemic and Hemorrhagic Strokes.
Hepatitis B
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
HIV Infections
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Homozygous Familial Hypercholesterolemia
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Hydrocephalus
Pafah1b2 mutations suppress the development of hydrocephalus in compound Pafah1b1; Reln and Pafah1b1; Dab1 mutant mice.
Hypercholesterolemia
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Oxidized LDL induces procoagulant profiles by increasing lysophosphatidylcholine levels, lysophosphatidylethanolamine levels, and Lp-PLA2 activity in borderline hypercholesterolemia.
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of the lipoprotein-associated phospholipase A2-bound apoB.
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Hyperemia
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Hyperglycemia
The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
Hyperhomocysteinemia
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Hyperinsulinism
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Hyperlipidemias
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
Lipoprotein-associated phospholipase A2 and serum lipid levels in subjects with chronic periodontitis and hyperlipidemia.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Hyperlipoproteinemia Type II
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Hypersensitivity
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014.
Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study.
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Hypertension
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Activity of platelet-activating-factor-acetylhydrolase and the nitric oxide metabolite level in the plasma of pregnant women who develop transient hypertension during later pregnancy.
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.
Association of sixty-one non-synonymous polymorphisms in forty-one hypertension candidate genes with blood pressure variation and hypertension.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Comparison of serum Lp-PLA2 levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension.
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.
Effects of overweight and the PLA2G7 V279F polymorphism on the association of age with systolic blood pressure.
Elevated Lipoprotein-Associated Phospholipase A2 Independently Affects Age-Related Increases in Systolic Blood Pressure: A Nested Case-Control Study in a Prospective Korean Cohort.
Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.
Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension.
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
MicroRNA-212-5p and its target PAFAH1B2 suppress vascular proliferation and contraction via the downregulation of RhoA.
Negative association between lipoprotein associated phospholipase A2 activity and baroreflex sensitivity in subjects with high normal blood pressure and a positive family history of hypertension.
OS 01-01 ASSOCIATION OF Lp-PLA2 MASS AND AYSMPTOMATIC INTRACRANIAL AND EXTRACRANIAL ARTERIAL STENOSIS IN HYPERTENSION PATIENTS.
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study.
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Hypertension, Pulmonary
Circulating plasma platelet activating factor in persistent pulmonary hypertension of the newborn.
Hypertriglyceridemia
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Glycoprotein Ibalpha polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients.
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Hypobetalipoproteinemias
Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Hypogonadism
The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency.
Hypotension
Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase.
Infant, Newborn, Diseases
Serum PAF acetylhydrolase increases during neonatal maturation.
Infections
A Neutralizing Monoclonal IgG1 Antibody of Platelet-Activating Factor Acetylhydrolase SsE Protects Mice against Lethal Subcutaneous Group A Streptococcus Infection.
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
Contemporary Pharyngeal and Invasive emm1 and Invasive emm12 Group A Streptococcus Isolates Exhibit Similar In Vivo Selection for CovRS Mutants in Mice.
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion.
High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response.
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Lipid mediators and vector infection: Trypanosoma rangeli inhibits Rhodnius prolixus hemocyte phagocytosis by modulation of phospholipase A2 and PAF-acetylhydrolase activities.
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Platelet-activating factor acetylhydrolase activity in cerebrospinal fluid of children with acute systemic or neurological illness.
Requirement and Synergistic Contribution of Platelet-Activating Factor Acetylhydrolase Sse and Streptolysin S to Inhibition of Neutrophil Recruitment and Systemic Infection by Hypervirulent
Serum platelet-activating factor acetylhydrolase and paraoxonase-1 activity in horses infected with Leptospira spp.
The Effect of the Leptin Receptor Q223R Polymorphism on the Host Transcriptome Following Infection with E. histolytica.
[Inflammation in atherosclerosis]
Inflammatory Bowel Diseases
Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease.
Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.
Influenza, Human
High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
Preliminary Proteomic Analysis of A549 Cells Infected with Avian Influenza Virus H7N9 and Influenza A Virus H1N1.
YesT: a new rhamnogalacturonan acetyl esterase from Bacillus subtilis.
Insulin Resistance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.
CONDITIONING FACTORS FOR HIGH CARDIOVASCULAR RISK IN PATIENTS WITH CUSHING SYNDROME.
Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice.
Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves.
Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity.
Resistin is an inflammatory marker of atherosclerosis in humans.
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance.]
Insulinoma
The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase.
Intestinal Polyposis
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Intracranial Hemorrhages
[Association between platelet-activating factor acetylhydrolase gene polymorphism and intracranial hemorrhage in preterm infants].
Intracranial Thrombosis
Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis.
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Irritable Bowel Syndrome
PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.
Ischemic Attack, Transient
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia.
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
Ischemic Stroke
A novel prognosis prediction model, including cytotoxic T lymphocyte-associated antigen-4, ischemia-modified albumin, lipoprotein-associated phospholipase A2, glial fibrillary acidic protein, and homocysteine, for ischemic stroke in the Chinese hypertensive population.
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Association of Lp-PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population.
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.
Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population.
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
Associations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke.
Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A2 for assessment of cardiovascular diseases.
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
Comparison of serum Lp-PLA2 levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension.
Free fatty acids to predict recurrent ischemic stroke.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis.
Influence of lipoprotein-associated phospholipase A2 mass on prognosis value of baseline platelet count for clinical outcomes after acute ischemic stroke.
Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke.
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.
Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.
Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
OS 01-01 ASSOCIATION OF Lp-PLA2 MASS AND AYSMPTOMATIC INTRACRANIAL AND EXTRACRANIAL ARTERIAL STENOSIS IN HYPERTENSION PATIENTS.
Phospholipase A2 and Ischemic Stroke Etiology.
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients?
Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke.
Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke: Methodological issues.
Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.
Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients.
Reply to: "Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke: Methodological issues".
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke.
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
[Association of serum lipoprotein-associated phospholipase A2 with vascular dementia after ischemic stroke].
[Clinical role of lipoprotein-associated phospholipase A2].
[Lipoprotein associated phospholipase A2].
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
[Meta-analysis for the relationship between lipoprotein-associated phospholipase A2 and ischemic stroke].
Kidney Failure, Chronic
Effect of a single hemodialysis session on endothelial dysfunction.
Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure.
Lecithin Cholesterol Acyltransferase Deficiency
Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
Leptospirosis
Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model.
Serum activity of platelet-activating factor acetylhydrolase is a potential clinical marker for leptospirosis pulmonary hemorrhage.
Lipid Metabolism Disorders
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Lissencephaly
A de novo microdeletion involving PAFAH1B (LIS1) related to lissencephaly phenotype.
Characterization and chromosomal mapping of two pseudogenes of the mouse Pafaha/Lis1 gene: retrointegration hotspots in the mouse genome.
Direct association of LIS1, the lissencephaly gene product, with a mammalian homologue of a fungal nuclear distribution protein, rNUDE.
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality.
Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly.
Involvement of platelet-activating factor and LIS1 in neuronal migration.
Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Previously uncharacterized roles of platelet-activating factor acetylhydrolase 1b complex in mouse spermatogenesis.
Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit.
Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis.
Liver Cirrhosis, Biliary
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Liver Diseases
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study.
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
[Challenges in liver diseases and transplantation].
Liver Neoplasms
Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats.
Lung Diseases
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia.
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Lung Injury
Elevated truncated oxidized phospholipids as a factor exacerbating ALI in the aging lungs.
Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: effects of hyperoxia.
Lung Neoplasms
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Is there a role of platelet-activating factor in human lung cancer?
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Lupus Erythematosus, Systemic
PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Lyme Disease
Peroxidative metabolism of arachidonic acid in the course of Lyme arthritis.
Lymphatic Metastasis
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Lymphoma
Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?
Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma.
Lymphoma, B-Cell
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Macular Degeneration
Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models.
Lipoprotein-associated phospholipase A2 and risk of age-related macular degeneration: the Rotterdam Study.
Macular Edema
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema: A 3-Month Placebo-Controlled Study.
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Lipoprotein-associated phospholipase A2: The story continues.
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Malformations of Cortical Development, Group II
Involvement of platelet-activating factor and LIS1 in neuronal migration.
Predominant localization of the LIS family of gene products to Cajal-Retzius cells and ventricular neuroepithelium in the developing human cortex.
Meningioma
Analysis of several PLA2 mRNA in human meningiomas.
Platelet-activating factor and human meningiomas.
Meningitis
Detection and characterization of 45 kDa platelet activating factor acetylhydrolase in cerebrospinal fluid of children with meningitis.
Metabolic Diseases
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases.
Metabolic Syndrome
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Carriage of the V279F homozygous genotype, a rare allele, within the gene encoding Lp-PLA2 leads to changes in circulating intermediate metabolites in individuals without metabolic syndrome.
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases.
Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Migraine Disorders
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Migraine without Aura
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Mucocutaneous Lymph Node Syndrome
A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease.
Elevated Levels of Platelet Activating Factor and Its Acetylhydrolase Indicate High Risk of Kawasaki Disease.
Serum Lp-PLA2 Level Predicting Coronary Artery Lesions in Children with Kawasaki Disease.
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
Multiple Sclerosis
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Lp-PLA2: Inflammatory Biomarker of Vascular Risk in Multiple Sclerosis.
Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis.
Myocardial Infarction
A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction.
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe.
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.
Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction.
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
Endothelial function after ST-elevation myocardial infarction in patients with high levels of high-sensitivity CRP and Lp-PLA2: A substudy of the RESPONSE randomized trial.
Free fatty acids to predict recurrent ischemic stroke.
High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.
Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Lipoprotein-associated phospholipase A2 as a target of therapy.
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.
The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction.
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction.
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg.
Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction.
[Clinical role of lipoprotein-associated phospholipase A2].
Myocardial Ischemia
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
[Influence of Intensive Hypolipidemic Therapy on Blood Concentration of Lipoprotein-Associated Phospholipase A2 in Patients With Ischemic Heart Disease.]
Myoma
Platelet-activating factor acetylhydrolase isoforms I and II in human uterus. Comparisons with pregnant uterus and myoma.
Neoplasm Metastasis
Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers.
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Neoplasms
?3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models.
Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma.
Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease.
Association between FSP, CVHI, inflammatory cytokines and the incidence of primary stroke.
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
Catechin Attenuates Coronary Heart Disease in a Rat Model by Inhibiting Inflammation.
Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization.
Correlations between PAF-acether and tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids.
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Diagnostic marker signature for esophageal cancer from transcriptome analysis.
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats.
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor.
Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation.
Genetics of intracerebral hemorrhage: Insights from candidate gene approaches.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response.
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
Inflammatory markers in hyperlipidemia: from experimental models to clinical practice.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
New advances in drug discovery.
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Overview of PAF-Degrading Enzymes.
Oxidative damage in dengue fever.
PAF and hematopoiesis. II. Elevated levels of plasma paf acetylhydrolase after rapid infusion of 5-fluorouracil in cancer patients.
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.
Relation of multiple inflammatory biomarkers to incident atrial fibrillation.
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.
Resistin is an inflammatory marker of atherosclerosis in humans.
Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models.
Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis.
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
[Inflammation in atherosclerosis]
[Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting].
Nephritis
No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis.
Nephrotic Syndrome
Release of platelet-activating factor in systemic lupus erythematosus.
Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins.
Nervous System Diseases
?-Lactones: A Novel Class of Ca2+-Independent Phospholipase A2 (Group VIA iPLA2) Inhibitors with Ability to Inhibit ?-Cell Apoptosis.
Neuroblastoma
Effect of retinoic acid on the Ca2+-independent phospholipase A2 in nuclei of LA-N-1 neuroblastoma cells.
Neuroinflammatory Diseases
Role of Ca2+-independent phospholipase A2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid production in brain: perspectives for protection in neuroinflammation.
Neutropenia
Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver.
Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor.
Non-alcoholic Fatty Liver Disease
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study.
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
[Challenges in liver diseases and transplantation].
Non-ST Elevated Myocardial Infarction
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
[Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions].
Obesity
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children.
Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study.
Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study.
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Obesity, Abdominal
Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity.
Osteoarthritis
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Osteosarcoma
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Ovarian Neoplasms
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Overweight
Effects of overweight and the PLA2G7 V279F polymorphism on the association of age with systolic blood pressure.
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Pancreatic Neoplasms
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Pancreatitis
Beneficial effects of recombinant platelet-activating factor acetylhydrolase and BN 52021 on bacterial translocation in cerulein-induced pancreatitis.
Correlations Between LP-PLA2 Gene Polymorphisms and Susceptibility and Severity of Acute Pancreatitis in a Chinese Population.
Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis.
Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
Parkinson Disease
Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+.
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease.
Peanut Hypersensitivity
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Periodontal Diseases
Implication of PAF and acetylhydrolase (PAF-AH) activity in periodontal disease.
Lipoprotein-associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease.
Periodontitis
Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics.
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
Peripheral Arterial Disease
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Lipoprotein-associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects.
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Plague
Prognostic Value of Serum LP-PLA2 and hs-CRP in Unstable Atherosclerotic Plaques.
Pleural Effusion
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Pleurisy
Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.
Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases.
Pneumonia
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Human macrophages secrete platelet-activating factor acetylhydrolase. A mechanism for resolution of pulmonary inflammation.
Polycystic Ovary Syndrome
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome.
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance.]
[The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]
Postpartum Hemorrhage
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Pre-Eclampsia
Association of the G994T and R92H genotypes of platelet-activating factor acetylhydrolase with risk of preeclampsia in Chinese women.
Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia.
Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study.
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Maternal and fetal plasma platelet-activating factor-acetylhydrolase activity and distribution in pre-eclampsia.
Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia.
[The Ala379Val polymorphism of platelet-activating factor acetylhydrolase gene in Chinese patients with pre-eclampsia].
Prediabetic State
Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.
Prehypertension
Associations among oxidative stress, Lp-PLA2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension.
Primary Ovarian Insufficiency
Platelet-activating factor acetylhydrolase and premature ovarian failure.
Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.
Prostatic Neoplasms
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
Proteinuria
Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis.
Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy.
Psoriasis
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation.
Pulmonary Disease, Chronic Obstructive
Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Purpura
[Association between platelet-activating factor acetylhydrolase gene polymorphisms and gastrointestinal bleeding in children with Henoch-Schönlein purpura].
Renal Insufficiency
Biomarkers of aortic bioprosthetic valve structural degeneration.
Renal Insufficiency, Chronic
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.
Evaluation of Lipoprotein-Associated Phospholipase A2 as a Prognostic Biomarker in Chronic Kidney Disease.
PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
Paricalcitol effects on activities and metabolism of Platelet Activating Factor and on inflammatory cytokines in hemodialysis patients.
Reperfusion Injury
Platelet activating factor acetylhydrolase decreases lung reperfusion injury.
Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury.
Respiratory Distress Syndrome
G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene and lung ultrasound score as prognostic markers in evaluating the outcome of acute respiratory distress syndrome.
Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome.
Platelet-activating factor acetylhydrolase and acute respiratory distress syndrome: unanswered questions.
Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome.
Platelet-activating factor in surfactant preparations.
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Rheumatic Diseases
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Rhinitis
Phospholipase A2 mRNA expression in the nasal mucosa of healthy subjects and patients with seasonal allergic rhinitis.
Scabies
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
YesT: a new rhamnogalacturonan acetyl esterase from Bacillus subtilis.
Scleroderma, Systemic
Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis.
Seizures
Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Sepsis
Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model.
Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
PAF acetylhydrolase and arachidonic acid metabolite levels in patients with sepsis.
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.
Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis.
Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis.
The Systemic Mediator-Associated Response Test Identifies Patients in Failed Sepsis Clinical Trials Among Whom Novel Drugs Reduce Mortality.
Shock, Septic
Accumulation of platelet-activating factor acetylhydrolase in the peritoneal cavity of guinea pig after endotoxin shock.
Class A CpG Oligonucleotide Priming Rescues Mice from Septic Shock via Activation of Platelet-Activating Factor Acetylhydrolase.
Cloning, expression and characterization of plasma platelet-activating factor-acetylhydrolase from guinea pig.
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Purification and characterization of platelet-activating factor acetylhydrolase from peritoneal fluid obtained from guinea pigs after endotoxin shock.
The macrophage response to endotoxin requires platelet activating factor.
Sleep Apnea, Obstructive
Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.
Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome.
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
Spasm
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm.
Spinal Cord Injuries
High seminal platelet-activating factor acetylhydrolase activity in men with spinal cord injury.
ST Elevation Myocardial Infarction
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction.
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Stomach Ulcer
Serum platelet-activating factor acetylhydrolase activity in rats with gastric ulcers induced by water-immersion stress.
Stroke
A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Advantages of the lipoprotein-associated phospholipase A2 activity assay.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between FSP, CVHI, inflammatory cytokines and the incidence of primary stroke.
Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.
Association of neuroimaging markers of cerebral small vessel disease with short-term outcomes in patients with minor cerebrovascular events.
Butyphthalide in the treatment of massive Cerebral Infarction.
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Free fatty acids to predict recurrent ischemic stroke.
High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Hypothesis of "stroke-stop" formula: a tool for risk index determination in development of acute cerebrovascular disease in asymptomatic individuals with carotid stenosis.
Impact of innate inflammation in population studies.
Inflammatory markers and stroke.
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke.
Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.
LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 AS A MARKER OF VULNERABLE ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH INTERNAL CAROTID ARTERY STENOSIS.
Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke.
Lipoprotein-associated phospholipase A2 and risk of stroke.
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Lipoprotein-associated Phospholipase A2 during the Hyperacute Stage of Ischemic and Hemorrhagic Strokes.
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study.
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis.
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.
Phospholipase A2 and Ischemic Stroke Etiology.
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment.
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients?
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.
Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients.
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke.
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
[Cerebral atherosclerosis: a biomarker profile].
[Lipoprotein-associated phospholipase A(2) and stroke]
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
[Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke]
Stroke, Lacunar
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
[Analysis of 994(G--> T) mutation in the plasma platelet-activating factor acetylhydrolase gene in the patients with cerebral infarction]
Subarachnoid Hemorrhage
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Is Admission Lipoprotein-Associated Phospholipase A2 a Novel Predictor of Vasospasm and Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage?
Plasma Platelet Activating Factor-Acetylhydrolase Activity and the Levels of Free Forms of Bio-marker of Lipid Peroxidation in Cerebrospinal Fluid of Patients with Aneurysmal Subarachnoid Hemorrhage.
Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage.
Systemic Vasculitis
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
Tangier Disease
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
Thalassemia
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Thrombocytopenia
Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.
Thrombosis
Activation of PAF-acetylhydrolase by nicotine and cotinine and their possible involvement in arterial thrombosis.
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Effects of the Ala379Val polymorphism of lipoprotein-associated phospholipase A2 on thrombosis and inflammation in hypertensive patients.
Exclusion of the alpha2 subunit of platelet-activating factor acetylhydrolase 1b (PAFAH1B2) as a prothrombotic gene in a protein C-deficient kindred and population-based case-control sample.
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
[Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions].
Tooth Loss
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.
Tuberculosis, Pulmonary
Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma.
Uremia
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis.
Uveitis
The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis.
Vascular Calcification
The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2.
Vascular Diseases
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Impact of innate inflammation in population studies.
Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs.
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a)).
Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease.
Vasospasm, Intracranial
Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?
Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage.
Venous Thromboembolism
Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study.
Venous Thrombosis
Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.
Vertebrobasilar Insufficiency
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Virus Diseases
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Vitamin E Deficiency
Vitamin E differentially regulates the expression of peroxiredoxin-1 and -6 in alveolar type II cells.
Wound Infection
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.